Study of NRG-103 injection for recurrent high-grade glioma
Part of Cancer clinical trials.
This trial tests a new injection called NRG-103 for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard treatments. The goal is to see if it's safe and if it might help shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have a high-grade glioma (WHO Grade 3 or 4) that has come back or kept growing after treatment.
- Standard treatments (like chemo, radiation, or immunotherapy) have either stopped working or caused serious side effects.
- You cannot have had gene therapy or virus-based cancer treatment before.
- You must be able to have an MRI scan (no metal implants like pacemakers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
This study tests a combination of three treatments for newly diagnosed high-grade glioma: a drug called ADI-PEG 20, chemotherapy (temozolomide), and radiation therapy. The goal is to see if this combination is safe and effective for children and young adults with this type of brain or spinal cord tumor.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
This trial tests a new mRNA vaccine for people with a type of brain tumor called high-grade glioma that has come back or progressed. The vaccine is designed to help your immune system recognize and attack the tumor cells.
This trial tests an injection called NRG-103 given directly into the cavity where a recurrent brain tumor was removed. It is for people with glioblastoma that has come back and who have already had standard treatments.
This trial tests a new drug called SRN-101 that is given directly into the brain tumor before surgery to remove it. The goal is to see if it is safe and could help people with a brain tumor that has come back after standard treatment.
Hear when a new HGG trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.